Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populations

• Published in: Breast cancer research : BCR 2014-07, Vol.16 (4), p.R71-R71, Article R71
• Main Authors: Wang, Dong-Yu, Done, Susan J, Mc Cready, David R, Leong, Wey L
• Format: Article
• Language: English
• Subjects: Adult; Aged; Analysis; Biomarkers, Tumor; Biotechnology industry; Breast Neoplasms - diagnosis; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Cancer; Cluster Analysis; Female; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic aspects; Genomics; Humans; Instrument industry; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Oncology, Experimental; Prognosis; Prospective Studies; Reproducibility of Results; Signal Transduction; Tumor Burden
• ISSN: 1465-542X; 1465-5411; 1465-542X
• DOI: 10.1186/bcr3686

Using genome-wide expression profiles of a prospective training cohort of breast cancer patients, ClinicoMolecular Triad Classification (CMTC) was recently developed to classify breast cancers into three clinically relevant groups to aid treatment decisions. CMTC was found to be both prognostic and predictive in a large external breast cancer cohort in that study. This study serves to validate the reproducibility of CMTC and its prognostic value using independent patient cohorts. An independent internal cohort (n = 284) and a new external cohort (n = 2,181) were used to validate the association of CMTC between clinicopathological factors, 12 known gene signatures, two molecular subtype classifiers, and 19 oncogenic signalling pathway activities, and to reproduce the abilities of CMTC to predict clinical outcomes of breast cancer. In addition, we also updated the outcome data of the original training cohort (n = 147). The original training cohort reached a statistically significant difference (p < 0.05) in disease-free survivals between the three CMTC groups after an additional two years of follow-up (median = 55 months). The prognostic value of the triad classification was reproduced in the second independent internal cohort and the new external validation cohort. CMTC achieved even higher prognostic significance when all available patients were analyzed (n = 4,851). Oncogenic pathways Myc, E2F1, Ras and β-catenin were again implicated in the high-risk groups. Both prospective internal cohorts and the independent external cohorts reproduced the triad classification of CMTC and its prognostic significance. CMTC is an independent prognostic predictor, and it outperformed 12 other known prognostic gene signatures, molecular subtype classifications, and all other standard prognostic clinicopathological factors. Our results support further development of CMTC portfolio into a guide for personalized breast cancer treatments.